Reactivity of Factor VIII Inhibitors in a Micro ELISA for Factor VIII : CAg and in Solid Phase Immunoisolation of VIII : CAg

Summary

Factor VIII coagulant antigen (VIII : CAg) was measured in a sandwich-ELISA. Microplates were used as solid phase and peroxidase conjugated F(ab’)2 fragments of IgG isolated from inhibitor plasma was used as label without affinity purification. The capacity of the assay was high and the sensitivity for VIII : CAg was 0.002 U/ml. Using this assay it was possible to measure coagulation inactive VIII : CAg in samples from purification studies. Below 0.05 VIII : CAg U/ml these samples responded in parallel with standard plasma.

Seven of 7 inhibitor antibodies tested were able to inhibit binding of peroxidase-conjugate in the VIII : CAg assay, and the inhibitory capacity correlated with coagulation inhibition as measured by the Bethesda method. Using the highest titered antibodies bound to a solid phase, VIII : CAg was isolated and identified in SDS-PAGE as a doublet with a molecular weight of 77-80 kD.

Keywords

Factor VIII : CAg - Solid phase immunoisolation - ELISA - Haemophilia A inhibitor antibodies

• References

• 1 Firschein SI, Hoyer LW, Lazarchick J, Forget BG, Hobbins JC, Clyne JC, Clyne LP, Pitlick FA, Muir WA, Merkatz IR, Mahoney MJ. Prenatal diagnosis of classic hemophilia. N Eng J Med 1979; 300: 937-941
• 2 Peake IR, Newcombe RG, Davies BL, Furlong RA, Ludlam CA, Bloom AL. Carrier detection in haemophilia A by immunological measurement of factor VIII related antigen (VIII:RAg) and factor VIII clotting antigen (VIII:CAg). Br J Haematol 1981; 48: 651-666
• 3 Lazarchick J, Hoyer LW. Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 1978; 62: 1048-1052
• 4 Girma JP, Lavergne JM, Meyer D, Larrieu MJ. Immunoradiometric assay of factor VIII coagulant antigen using four human antibodies. Br J Haematol 1981; 47: 269-281
• 5 Aledort LM, Pannekoek H, Vehar GA, Veltkamp JJ. What is the prospective impact of the recombinant DNA technique on the production of human plasma derivatives. Vox Sang 1983; 44: 390-395
• 6 Bloom AL. Benefits of cloning genes for clotting factors. Nature 1983; 303: 474-475
• 7 Muller HP, Van Tilburg NH, Bertina RM, Veltkamp JJ. Immunologic studies on the relationship between F. VIII procoagulant activity. Thromb Res 1980; 20: 85-96
• 8 Tran TH, Duckert F. Dissociation of factor VIII procoagulant antigen VIII : CAg and factor VIII related antigen VIII : Ag by EDTA- Influence of divalent cation binding on the binding of VIII : CAg and VIIIR : Ag. Thromb Haemostas 1983; 50: 547-551
• 9 Dinesen B, Feddersen C. An enzyme immunoassay (ELISA) for the quantitation of human factor VIII coagulant antigen (VIII:CAg). Thromb Res 1983; 31: 707-718
• 10 Tamura GS, Dailey MO, Gallatin WM, Grath MC, Weissman IL, Pillemer EA. Isolation of molecules recognized by monoclonal antibodies and antisera: the solid phase immunoisolation technique. Anal Biochem 1984; 458-464
• 11 Kuo G, Craine B, Masiarz F, Rall L, Truett M, Valenzuela P, Nordfang O, Ezban M. Studies on the molecular structure of human factor VIII :C. Thromb Haemostas 1983; 50: 262 (Abstr.)
• 12 Spiegelberg HL. Theoretical considerations of antigen-antibody reactions and isolation of IgG and its fragments. Immunoassays in the Clinical Laboratory. Al Liss; New York: 1979. pp 1-22
• 13 Barrowcliffe TW, Tydeman MS, Kirkwood TB L, Thomas DP. Standardization of factor VIII-III. Establishment of a stable reference plasma for factor VIII-related activities Thromb Haemostas 1983; 50: 690-696
• 14 Proctor RP, Rapaport SI. The partial thromboplastin time with kaolin. Am J Clin Pathol 1961; 36: 212-219
• 15 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratanti IJ, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shalman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorr 1975; 34: 869-872
• 16 Tuddenham EG D, Trabold NC, Collins JA, Hoyer LW. The properties of factor VIII coagulant activity prepared by immunosorbent chromatography. J Lab Clin Med 1979; 93: 40-53
• 17 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 18 Biggs R, Austen DE G, Denson KW E, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII. Br J Haematol 1972; 23: 125-135
• 19 Biggs R, Austen DE G, Denson KW E, Borrett R, Rizza CR. The mode of action of antibodies which destroy factor VIII. Br J Haematol 1972; 23: 137-155
• 20 Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13
• 21 Rotblat F, Tuddenham EG D. Immunologic studies of factor VIII coagulant activity assay based on a haemophilic and an acquired antibody to VIII:C. Thromb Res 1981; 21: 431-445
• 22 Stel HV, Veerman EC I, Huisman JC, Janssen MC, van Mourik JA. A rapid one-step immunoradiometric assay for factor VIII- procoagulant antigen utilizing monoclonal antibodies. Thromb Haemostas 1983; 50: 860-863
• 23 Brodén K, Brown JE, Carton C, Anderson LO. Effect of phospholipid on factor VIII coagulant activity and coagulant antigen. Thromb Res 1983; 30: 651-660
• 24 Furlong RW, Peake IR, Bloom AL. Factor VIII clotting antigen (VIII :CAg) in haemophilia measured by two immunoradiometric assays (IRMA) using different antibodies, and the measurement of inhibitors to procoagulant factor VIII (VIII :C) by IRMA. Br J Haematol 1981; 48: 643-650
• 25 Hellings JA, van Leeuwen FR, Over J, van Mourik JA. Immunoradiometric assay of VIII :CAg, a potential tool to detect human anti-VIII:C antibodies. Thromb Res 1982; 26: 297-302
• 26 Gawryl MS, Hoyer LW. Immunologic studies of antihemophilic factor (AHF, VIII :C). Clin Immunol Immunopathol 1982; 23: 517-526
• 27 Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648-1652
• 28 Fulcher CA, Roberts JR R, Zimmerman TS. Thrombin proteolysis of purified factor VIII procoagulant protein: correlation of activation with generation of specific polypeptide. Blood 1983; 61: 807-811
• 29 Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 321: 326-330
• 30 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kafuman RJ, Brown E, Shoemarker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick PM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 321: 342-347
• 31 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Opperman H, Keck R, Wood WI, Harkins RN, Tuddenham EG D, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342
• 32 Chediak J, Peake I, Bloom A. Gelfiltration of factor VIII coagulant antigen and factor VIII related antigen in normal and von Wille- brand’s disease. Thromb Haemostas 1983; 50: 509-512
• 33 Mikaelsson ME, Forsman N, Oswaldsson VM. Human factor VIII: a calcium linked protein complex. Blood 1983; 62: 1006-1015